CAJ | 학술논문

目的：系统性评价利奈唑胺对2013~2014年耐甲氧西林金黄色葡萄球菌（MRSA）临床分离株细菌生物膜（BBF）的活性及体内外抗菌效果。方法：体外试验测定最低抑菌浓度（MIC）；最低杀菌浓度（MBC）；最小抑制BBF浓度（MBIC）和最低BBF消除浓度（MBEC）；活菌计数法绘制时间-杀菌曲线（KCs）；体内试验采用小鼠MRSA全身感染模型，尾静脉给药保护小鼠后测定半数有效剂量（ED50）；建立免疫低下小鼠MRSA大腿感染模型，记录尾静脉给药24 h后大腿组织菌量的变化。结果：利奈唑胺对2013~2014年临床分离的60株MRSA均敏感；对金黄色葡萄球菌BBF的MBIC值与万古霉素相当，敏感性显著高于阿莫西林；体内试验中，利奈唑胺对全身感染小鼠有很好的治疗效果，ED50小于万古霉素与阿莫西林；对免疫低下MRSA大腿感染模型小鼠的保护作用也要优于万古霉素和阿莫西林。结论：利奈唑胺对2013~2014年分离的MRSA临床菌株体内外活性均较高，尤其对MRSA的细菌生物膜也显示了极强的抑制作用。
목적：계통성평개리내서알대2013~2014년내갑양서림금황색포도구균（MRSA）림상분리주세균생물막（BBF）적활성급체내외항균효과。방법：체외시험측정최저억균농도（MIC）；최저살균농도（MBC）；최소억제BBF농도（MBIC）화최저BBF소제농도（MBEC）；활균계수법회제시간-살균곡선（KCs）；체내시험채용소서MRSA전신감염모형，미정맥급약보호소서후측정반수유효제량（ED50）；건립면역저하소서MRSA대퇴감염모형，기록미정맥급약24 h후대퇴조직균량적변화。결과：리내서알대2013~2014년림상분리적60주MRSA균민감；대금황색포도구균BBF적MBIC치여만고매소상당，민감성현저고우아막서림；체내시험중，리내서알대전신감염소서유흔호적치료효과，ED50소우만고매소여아막서림；대면역저하MRSA대퇴감염모형소서적보호작용야요우우만고매소화아막서림。결론：리내서알대2013~2014년분리적MRSA림상균주체내외활성균교고，우기대MRSA적세균생물막야현시료겁강적억제작용。
Objective: To systematically research the antimicrobial activity of Linezolid against methicillin-resistant Staphylococcus aureus (MRSA) from 2013~2014 in vitro and in vivo. Methods:Minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC), minimal bacterial biofilm inhibitory concentration (MBIC) and minimal bacterial biofilm eradication concentration (MBEC) were determined in vitro. The time-killing curves (KCs) were drawn by live bacteria counting method. In vivo tests, the model of systemic infection with MRSA was established in mice, the mice were treated with linezolid by intravenous injection for the calculation of ED50. With the established immunodeficiency mouse model of thigh infection with MRSA, CFU in the thighs were counted 24 hours after the administration of linezolid by intravenous injection. Results: Linezolid was sensitive to all 60 clinically isolated MRSA. The MBIC of linezolid against MRSA bacterial biofilm were similar to those of Vancomycin, its sensitivity was significantly higher than that of Amoxicillin. In vivo, linezolid had better effects against systemic MRSA infection and thigh muscle MRSA infection compared with those of Vancomycin and Amoxicillin. Conclusion: Linezolid has excellent antibacterial activity against MRSA in vitro and in vivo.